SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SIGHINOLFI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.534
AS - Asia 1.276
EU - Europa 1.056
SA - Sud America 204
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.103
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.470
PL - Polonia 570
SG - Singapore 556
CN - Cina 324
BR - Brasile 168
HK - Hong Kong 130
IT - Italia 111
VN - Vietnam 105
DE - Germania 97
ID - Indonesia 73
GB - Regno Unito 70
RU - Federazione Russa 44
SE - Svezia 36
CA - Canada 32
FI - Finlandia 31
MX - Messico 26
IN - India 18
NL - Olanda 18
AT - Austria 17
JP - Giappone 16
ES - Italia 15
AR - Argentina 14
UA - Ucraina 14
ZA - Sudafrica 14
FR - Francia 13
BD - Bangladesh 12
TH - Thailandia 7
IQ - Iraq 6
KE - Kenya 6
TR - Turchia 6
AE - Emirati Arabi Uniti 5
IE - Irlanda 5
LT - Lituania 4
VE - Venezuela 4
BE - Belgio 3
CL - Cile 3
CO - Colombia 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
EG - Egitto 3
EU - Europa 3
PE - Perù 3
PH - Filippine 3
PK - Pakistan 3
PY - Paraguay 3
IL - Israele 2
JM - Giamaica 2
MA - Marocco 2
MY - Malesia 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BO - Bolivia 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
RO - Romania 1
RW - Ruanda 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 5.103
Salva come PNG Salva come JPEG
Città #
Warsaw 569
Ashburn 431
Fairfield 331
Singapore 271
Beijing 206
Santa Clara 206
Woodbridge 145
Seattle 133
Hong Kong 130
Houston 117
Wilmington 113
Cambridge 101
Chandler 87
Jakarta 70
Dallas 60
Dong Ket 52
Los Angeles 49
Princeton 46
Ann Arbor 36
San Diego 33
Munich 31
New York 25
Ho Chi Minh City 24
Turku 24
São Paulo 23
Ferrara 22
Nuremberg 22
Washington 21
Bremen 20
London 20
Mexico City 18
Tokyo 16
Montreal 15
Shanghai 15
Hanoi 14
Santa Maria Di Sala 14
Buffalo 13
Bologna 12
Brooklyn 11
Portsmouth 11
Stockholm 11
Boston 10
Johannesburg 10
Chicago 9
Falls Church 9
Lauterbourg 9
Redwood City 9
Vienna 9
Chennai 7
Milan 7
Padova 7
Moscow 6
Orem 6
San Francisco 6
The Dalles 6
Toronto 6
Umeå 6
Utrecht 6
Belo Horizonte 5
Denver 5
Helsinki 5
Porto Alegre 5
Tianjin 5
Verona 5
Addison 4
Atlanta 4
Augusta 4
Birmingham 4
Brasília 4
Charlotte 4
Chiswick 4
Dhaka 4
Frankfurt am Main 4
Jacksonville 4
Nairobi 4
Poplar 4
Rio de Janeiro 4
Rome 4
Vancouver 4
Amsterdam 3
Annapolis 3
Athens 3
Blumenau 3
Boardman 3
Brussels 3
Calgary 3
Can Tho 3
Cape Town 3
Chipping Norton 3
Cordenons 3
Da Nang 3
Dublin 3
Fulham 3
Goiânia 3
Guangzhou 3
Jinan 3
Manchester 3
Mountain View 3
North Wales 3
Norwalk 3
Totale 3.849
Salva come PNG Salva come JPEG
Nome #
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation 213
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 191
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 161
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 149
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 145
A Comparison Between Different Anti-Retroviral Therapy Regimes on Soluble Inflammation Markers: a Pilot Study 145
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 136
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 135
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 134
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 134
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 129
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 129
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 124
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 123
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 123
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 116
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 115
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 112
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 110
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 109
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 108
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 106
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 106
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 105
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 103
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 101
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 98
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 97
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 97
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 95
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 95
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 94
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 94
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 94
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 93
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 92
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 90
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 89
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 85
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 85
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 77
ANTIRETROVIRAL THERAPY RESTORES NAÏVE T CELL FREQUENCIES OC 8 AND FUNCTIONALITY IN PLWH 75
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 75
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 65
IMMUNOSENESCENCE FEATURES ARE PARTIALLY RESTORED BY ANTIRETROVIRAL THERAPY 60
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 60
null 46
Totale 5.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.372
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.372
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021814 0 0 0 0 0 183 142 116 74 183 19 97
2021/2022339 41 18 2 5 15 44 21 27 16 39 12 99
2022/2023252 47 10 9 11 44 25 10 36 34 2 16 8
2023/2024334 14 27 29 14 46 91 11 7 5 3 2 85
2024/20251.130 25 11 115 25 138 140 32 36 175 157 148 128
2025/20261.350 290 106 246 258 419 31 0 0 0 0 0 0
Totale 5.267